

Info Sheet for Technical description

No. 0008 - 1

Organization

* Mandatoty fields

Name of Organization*	Metcela Inc.	
Address, City, States, Zip, Country*	CYBERNICS MEDICAL INNOVATION BASE-A 129, 3-25-16 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-087	
URL	https://www.metcela.com/en/	
Brief Descriptions of Organization* (Approx. 100 words)	Metcela Inc., established in 2016, is a clinical-stage biotechnology startup pioneering the research and development of fibroblast and stem cell-based therapy for chronic diseases that currently have limited therapeutic options. MTC001 is a combination product of autologous cardiac cells (VCAM-1-positive Cardiac Fibroblast, VCF) and a novel catheter delivery system targeting chronic heart failure patients. MTC001 offers two major advantages over other cell therapies: (1) the therapeutic cells are autologous (patient-derived) and homologous (tissue-specific i.e. cardiac-derived), which is most suitable for the heart, as it is a highly immunogenic organ, and (2) the minimally invasive catheter system is equipped with a highly functional injection needle specifically designed for this therapy to achieve reliable and safe administration of the cells.	
Contact address	Name*	Metcela Corporate Development
	Department* / Position	Corporate Development Dept.
	E-mail* / TEL	cd@metcela.com

What kind of technology do you want to offer? *

- A.** Clinical Development Pipelines → Please see **Sheet [A]**
- B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc. → Please see **Sheet [B]**
- C.** Platform Technologies(*) that are not included in the above (Group B) → Please see **Sheet [C]**

* Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

- Yes
- No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- Angel / Seed (including AMED/JST grants)
- Series A
- Series B
- Series C
- Series D or further advanced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
<input checked="" type="checkbox"/> Yes	
<input type="checkbox"/> No	

Filled in by*

Keiji Arimura, CFO

Date*

2023/9/14

Info Sheet for Technical overview

No. 0008 - 1

* Mandatoty fields

Title*

Fibroblast-Catheter Therapy: Redefining Heart Failure Treatment

Development Phase*

- | | | |
|--|--|---|
| <input type="checkbox"/> Basic Research | <input type="checkbox"/> Drug Discovery | <input type="checkbox"/> Pre-Clinical |
| <input checked="" type="checkbox"/> Clinical Trial (Phase I) | <input type="checkbox"/> Clinical Trial (Phase II) | <input type="checkbox"/> Clinical Trial (Phase III) |
| <input type="checkbox"/> Review | <input type="checkbox"/> Others | |


Disease Area*

- | | | |
|--|---|--|
| <input type="checkbox"/> Cancer | <input type="checkbox"/> Central nervous system | <input type="checkbox"/> Ophthalmology |
| <input type="checkbox"/> Musculoskeletal | <input type="checkbox"/> Endocrine / Metabolism | <input checked="" type="checkbox"/> Cardiovascular |
| <input type="checkbox"/> Urogenital | <input type="checkbox"/> Digestive organ | <input type="checkbox"/> Blood |
| <input type="checkbox"/> Infection | <input type="checkbox"/> Dermatology | <input checked="" type="checkbox"/> Immunity |
| <input type="checkbox"/> Otolaryngology | <input type="checkbox"/> Respiratory | <input checked="" type="checkbox"/> Others |

Description*

MTC001 is a combination product of autologous cardiac fibroblast cells and a delivery catheter system targeting adult ischemic heart failure. MTC001 is in Ph1 clinical trial at University of Tsukuba.

Ischemic heart failure is one of leading cause of death worldwide. There are limited therapeutic options as these patients are often prescribed medications to delay the progress and relieve some of the symptoms. Ultimately heart transplant is the only curative options, yet the number of waitlisted patients increase every year. MTC001 is a combination product of our proprietary fibroblasts called VCF and a catheter system for cell administration. Metcela believes that delivery method for cell-based therapy for the heart is as important as the cells itself. Collaborating with a Japanese catheter company and cardiologists, we specifically designed a new delivery catheter to precisely administer VCF to the targetted regions. The injection needle has a unique shape for better cell retention when injected, and the catheter connects to an approved and widely used 3D mapping system for precise visualization of the infarct and accurate injection of the cells. Combining this delivery system and VCF, we have initiated our first clinical trial for MTC001 at the University of Tsukuba hospital.



Filled in by*

Keiji Arimura, CFO

Date*

2023/9/14